User:Mr. Ibrahem/Pimavanserin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Pimavanserin
Clinical data
Trade namesNuplazid
Other namesACP-103; BVF-048
AHFS/Drugs.comMonograph
Routes of
administration		By mouth (tablets)
Drug classAtypical antipsychotic
Legal status
Legal status
Pharmacokinetic data
Protein binding94–97%[1]
MetabolismLiver (CYP3A4, CYP3A5, CYP2J2)[2]
Elimination half-life54–56 hours[1]
Identifiers
  • N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
Chemical and physical data
FormulaC25H34FN3O2
Molar mass427.564 g·mol−1
3D model (JSmol)
  • CC(C)COc3ccc(cc3)CNC(=O)N(C(CC2)CCN2C)Cc(cc1)ccc1F
  • InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30) ☒N
  • Key:RKEWSXXUOLRFBX-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Pimavanserin, sold under the brand name Nuplazid, is an medication used to treat psychosis in Parkinson's disease.[3] It is not recommended for psychosis due to dementia.[3] It is taken by mouth.[3]

Common side effects include swelling and confusion.[4] Other side effects may include QT prolongation.[4] Use in not recommended in those with liver problems.[3] It is an atypical antipsychotic.[3] How it works is not clear but may involved effects on serotonin receptors.[3]

Pimavanserin was approved for medical use in the United States in 2016.[3] It is not approved in Europe or the United Kingdom as of 2021.[5] In the United States it costs about 4,200 USD per month as of 2021.[6]

References[edit]

  1. ^ a b Friedman JH (October 2013). "Pimavanserin for the treatment of Parkinson's disease psychosis". Expert Opinion on Pharmacotherapy. 14 (14): 1969–75. doi:10.1517/14656566.2013.819345. PMID 24016069. S2CID 35649566.
  2. ^ "Nuplazid (pimavanserin) Tablets, for Oral Use. U.S. Full Prescribing Information" (PDF). ACADIA Pharmaceuticals Inc. Archived from the original (PDF) on 3 October 2018. Retrieved 5 Nov 2018.
  3. ^ a b c d e f g h i "Pimavanserin Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 28 October 2021.
  4. ^ a b c "DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet, coated". dailymed.nlm.nih.gov. Archived from the original on 4 May 2021. Retrieved 28 October 2021.
  5. ^ "Pimavanserin". SPS - Specialist Pharmacy Service. 1 January 2016. Archived from the original on 28 October 2021. Retrieved 28 October 2021.
  6. ^ "Nuplazid Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 28 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Pimavanserin&oldid=1222028386"